ProCE Banner Activity

Histology-Agnostic Biomarkers for GI Cancers and Biomarker-Driven Treatment of Advanced Colorectal Cancer

Slideset Download
Download this slideset for expert perspectives on best practices in testing for tumor-agnostic and CRC-specific biomarkers—including MSI/MMR, TMB, NTRK fusions, BRAF/RAS mutations, and HER2 amplifications—and use of related targeted therapeutics. 

Released: January 21, 2022

Expiration: January 20, 2023

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Merck, Pfizer, and Taiho and salary from Indivumed.